- Dermata Therapeutics, Inc. (DRMA) presented **positive clinical data** from its **XYNGARI™ (DMT310) Phase 3 Spongilla Treatment of Acne (STAR-1) clinical trial** at the European Academy of Dermatology and Venereology Congress 2025.  **[1853816_0001493152-25-013815_form8-k.htm:1]** 
- The trial demonstrated **statistically significant differences** in Investigator Global Assessment (IGA) treatment success for XYNGARI™ compared to placebo at weeks 4, 8, and 12.  **[1853816_0001493152-25-013815_form8-k.htm:1]**  At week 12, **29.4%** of XYNGARI™ patients achieved IGA treatment success (2-point reduction and score of 0 or 1) versus **15.2%** for placebo (p < 0.001).  **[1853816_0001493152-25-013815_form8-k.htm:1]** 
- XYNGARI™ also showed **statistically significant improvements** in mean and percent change from baseline for both inflammatory and non-inflammatory lesion counts at weeks 4, 8, and 12 compared to placebo.  **[1853816_0001493152-25-013815_form8-k.htm:1]**  For example, at week 12, the percent change from baseline in inflammatory lesion count was **59.1%** for XYNGARI™ versus **45.3%** for placebo (p < 0.001).  **[1853816_0001493152-25-013815_form8-k.htm:1]**

Dermata Therapeutics (DRMA)